Systemic sclerosis: markers and targeted treatments

Area of Science:

• Immunology and Rheumatology
• Vascular Biology
• Fibrosis Research

Background:

• Systemic sclerosis (SSc) is an autoimmune disease characterized by autoantibody production, microvasculopathy, and excessive extracellular matrix (ECM) deposition.
• Key clinical features include Raynaud's phenomenon (RP) and skin involvement, with potential for internal organ damage.
• Current treatments address symptoms and organ-specific issues, but effective disease-modifying markers and targets remain under investigation.

Purpose of the Study:

• To review current and emerging therapeutic strategies for Systemic Sclerosis (SSc).
• To highlight the importance of targeting early disease hallmarks: microvascular damage and autoimmune responses.
• To explore the potential of epigenetic studies, particularly microRNAs, for future SSc diagnostics and therapeutics.

Main Methods:

• Review of existing literature on SSc pathophysiology and treatment modalities.
• Analysis of therapies targeting vascular, immune, and fibrotic pathways.
• Consideration of advanced treatments like hematopoietic stem cell transplantation (HSTC) and intravenous immunoglobulins (IVIG).

Main Results:

• Various therapies targeting vasculature (e.g., endothelin-1 receptor antagonists, PDE-5 inhibitors), immune system (e.g., DMARDs, biologics), and fibrosis are under evaluation.
• Advanced treatments like HSTC and IVIG are options for refractory SSc.
• Epigenetic research, specifically microRNAs, shows promise for novel diagnostic and therapeutic approaches.

Conclusions:

• Combination therapy is considered the optimal approach for SSc management.
• Early intervention targeting microvascular dysfunction and autoimmune reactions is crucial for "at-risk" patients.
• Future SSc management will likely integrate epigenetic insights and a multi-targeted therapeutic strategy.